These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20638324)

  • 1. Design of next-generation protein therapeutics.
    Caravella J; Lugovskoy A
    Curr Opin Chem Biol; 2010 Aug; 14(4):520-8. PubMed ID: 20638324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular engineering and design of therapeutic antibodies.
    Presta LG
    Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creating the next generation of protein therapeutics through rational drug design.
    Szymkowski DE
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):590-600. PubMed ID: 16159021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction to current and future protein therapeutics: a protein engineering perspective.
    Carter PJ
    Exp Cell Res; 2011 May; 317(9):1261-9. PubMed ID: 21371474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging SBDD in protein therapeutic development: antibody engineering.
    Gilliland GL; Luo J; Vafa O; Almagro JC
    Methods Mol Biol; 2012; 841():321-49. PubMed ID: 22222459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody modeling: implications for engineering and design.
    Morea V; Lesk AM; Tramontano A
    Methods; 2000 Mar; 20(3):267-79. PubMed ID: 10694450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating cell-level kinetic modeling into the design of engineered protein therapeutics.
    Rao BM; Lauffenburger DA; Wittrup KD
    Nat Biotechnol; 2005 Feb; 23(2):191-4. PubMed ID: 15696150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic antibody production technologies: molecules, applications, expression and purification.
    Humphreys DP; Glover DJ
    Curr Opin Drug Discov Devel; 2001 Mar; 4(2):172-85. PubMed ID: 11378956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabodies: molecular engineering and therapeutic applications.
    Wu C
    Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative non-antibody scaffolds for molecular recognition.
    Skerra A
    Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
    Huang C
    Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies and genetically engineered related molecules: production and purification.
    Roque AC; Lowe CR; Taipa MA
    Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins.
    Kolmar H
    FEBS J; 2008 Jun; 275(11):2684-90. PubMed ID: 18435757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-hairpin peptidomimetics: design, structures and biological activities.
    Robinson JA
    Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.